Investigating new treatments for lung injury caused by viruses
Official title: RXR/PPARg heterodimer agonists for treating virus-induced acute lung injury
Funded at Sigmovir Biosystems, INC. · NIH-10952071 · Data updated 2026-11-12
This study is looking at how special immune cells in your lungs respond to viral infections that can cause serious breathing problems, and it aims to find new ways to help heal your lungs if you have conditions like ARDS.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sigmovir Biosystems, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | August 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $75,500 |
| NIH project number | 1R03AI186104-01 |
| Project ID | NIH-10952071 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults who have experienced acute lung injury or respiratory distress due to viral infections.
✕Less likely to help
Patients with chronic lung diseases unrelated to viral infections may not benefit from this research.
What this research studies
This research focuses on understanding how certain immune cells, called macrophages, respond to viral infections that lead to acute lung injury. The study examines the different types of macrophages and their roles in either causing inflammation or helping to heal lung tissue. By exploring the effects of specific compounds that activate these macrophages, the research aims to find new therapeutic approaches to improve lung health in patients suffering from conditions like ARDS. The methodology includes using animal models to observe how these treatments affect lung recovery after viral infections.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery from virus-induced lung injuries.
How similar studies have gone: Previous research has shown promise in using similar approaches to modulate immune responses in lung injuries, indicating potential for success in this area.
Where this research is happening
-
Sigmovir Biosystems, INC.
Rockville, United States Active
Researchers
- Principal investigator: Blanco, Jorge C — Sigmovir Biosystems, INC.
- Study coordinator: Blanco, Jorge C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.